CSF3 and Decreased total neutrophil count: The authors of the CONVERT trial speculated that with prophylactic G-CSF, patients received the same dose intensity of chemotherapy in subsequent cycles instead of dose reduction after severe neutropenia, possibly resulting in a higher incidence of other myelosuppression.